Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer

Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer - ADC value during chemotherapy in pancreatic cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020809

Enrollment

Registered

2016-01-31

Start date

2008-02-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable pancreatic cancer

Interventions

MRI is performed 4 weeks after starting of chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (i) no prior treatment; (ii) maximum diameter of pancreas tumour >1 cm; (iii) Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 2; and (iv) adequate bone marrow, kidney and liver function.

Exclusion criteria

Exclusion criteria: the presence of a contraindication for magnetic resonance imaging

Design outcomes

Primary

Measure	Time frame
Relationship between ADC change and survival	—

Countries

Japan

Contacts

Public ContactHideyuki Nishiofuku

Nara Medical University Radiology

hmn@naramed-u.ac.jp0744-29-8900

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026